The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Stat proteins and oncogenesis
Open accessAbstract
JAK-STAT signaling in human diseaseThe discovery of Stat proteins' key role in IFN signaling, initially described over ten years ago, provided the first molecular link of growth factor receptor stimulation to the direct activation of a transcription factor (1). Since that time a large number of growth factor receptors and some nonreceptor tyrosine kinases have been found to lead to the activation of these transcription factors (2).The contributions of individual Stat proteins to normal cytokine signaling and development have been studied in various cell culture systems and in vivo in mice made deficient for one or more of these proteins (3).This approach has identified some related roles, as well as many unique, nonoverlapping physiological roles, for the various members of the Stat family.In summary, Stat1-deficient mice are unable to respond to IFNs and are subsequently susceptible to bacterial and viral pathogens.Likewise, disruption of Stat2 gives rise to animals unable to respond to type 1 IFNs, with increased susceptibility to viral infections (see Candotti et al., this Perspective series, ref. 4).Stat4-and Stat6-deficient animals reveal a requirement for IL-12-or IL-4-mediated proliferation of T cells, respectively (see Decker et al., this series, ref. 5).The phenotypes of Stat5A and Stat5B individual knockouts reveal the importance of Stat5A in breast development and lactation and the importance of Stat5B in the development of sexually dimorphic patterns of gene expression within the liver.In addition to these phenotypes, Stat5A/5B double knockouts are abnormal in their T cell and B cell development.Because Stat3-deficient animals die early in embryogenesis, the role of this protein in a number of biological functions had to be determined in conditional knockouts.As discussed by Levy and Lee in this series (6), Stat3 is implicated in keratinocyte migration, T cell apoptosis, IL-10-mediated signaling in macrophages, and the induction of apoptosis in the involuting breast.Beyond these various roles in normal cellular and physiological processes, the Stat proteins are now known to participate in cellular transformation and oncogenesis.Here, I consider the evidence implicating these molecules, particularly Stats 1, 3, and 5, in tumor formation and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Self-citationBowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743 · cited 1×
“Salient examples are seen in multiple myeloma, which characteristically overexpresses IL-6 and its receptor, and in head and neck cancers, where EGF and its receptor are found at high levels (29).”
BackgroundMeraz, M. A., White, J. M., Sheehan, K. C. F., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81288-x · Cited by 1,656
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease
Durbin, J. E., Hackenmiller, R., Simon, M. C., & Levy, D. E. (1996) · Cell · doi:10.1016/s0092-8674(00)81289-1 · Cited by 1,242
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
Self-citationThe role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201 · cited 1×
“Since that time a large number of growth factor receptors and some nonreceptor tyrosine kinases have been found to lead to the activation of these transcription factors (2).”
BackgroundSelf-citationInhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897
Research works printed but not linked: 4
- Bromberg, 1998, Cell Growth Differ, 9, 505
- 10.1038/88225 · doi:10.1038/88225
- 10.1016/S0304-3940(01)01711-6 · doi:10.1016/s0304-3940(01)01711-6
- Ivashkiv, 2000, Rev Immunogenet, 2, 220
Cited by
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
“2 ), which are signalling molecules that are involved in cell survival, proliferation, differentiation and apoptosi”
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
Levy, D. E., & Lee, C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15650 · Cited by 810
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
Levy, D. E., & Lee, C.-K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215650 · Cited by 734
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., & McCubrey, J. A. (2004) · Leukemia · doi:10.1038/sj.leu.2403241 · Cited by 684
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose-John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683
Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666
Self-citationSTAT proteins: From normal control of cellular events to tumorigenesis
Calò, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N., & Russo, A. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10364 · Cited by 610
Radaeva, S., Sun, R., Pan, H.-N., Hong, F., & Gao, B. (2004) · Hepatology · doi:10.1002/hep.20184 · Cited by 597
Harada, M., Qin, Y., Takano, H., Minamino, T., Zou, Y., Toko, H., Ohtsuka, M., Matsuura, K., Sano, M., Nishi, J.-I., et al. (2005) · Nature Medicine · doi:10.1038/nm1199 · Cited by 564
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555
“Activation of Stat3 has been observed in a variety of human tumors, including breast cancer, prostate cancer, head and neck cancer, colon cancer, lung cancer, and multiple myeloma (Bromberg, 2002).”
BackgroundMechanisms of Jak/STAT Signaling in Immunity and Disease
Villarino, A. V., Kanno, Y., Ferdinand, J. R., & O’Shea, J. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401867 · Cited by 552
The role of STAT3 in autophagy
You, L., Wang, Z., Li, H., Shou, J., Jing, Z., Xie, J., Sui, X., Pan, H., & Han, W. (2015) · Autophagy · doi:10.1080/15548627.2015.1017192 · Cited by 515
“Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3.”
BackgroundInfluentialSTAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells
Sherry, M. M., Reeves, A., Wu, J. K., & Cochran, B. H. (2009) · Stem Cells · doi:10.1002/stem.185 · Cited by 478
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
Aoki, Y., Feldman, G. M., & Tosato, G. (2003) · Blood · doi:10.1182/blood-2002-07-2130 · Cited by 438
Evans, C. J., Hartenstein, V., & Banerjee, U. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00335-6 · Cited by 433
Corvinus, F. M., Orth, C., Moriggl, R., Tsareva, S. A., Wagner, S., Pfitzner, E. B., Baus, D., Kaufman, R., Huber, L. A., Zatloukal, K., et al. (2005) · Neoplasia · doi:10.1593/neo.04571 · Cited by 427
AGGARWAL, B. B., SETHI, G., AHN, K. S., SANDUR, S. K., PANDEY, M. K., KUNNUMAKKARA, A. B., SUNG, B., & ICHIKAWA, H. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.063 · Cited by 398
Activation of Stat3 in Human Melanoma Promotes Brain Metastasis
Xie, T.-X., Huang, F.-J., Aldape, K. D., Kang, S.-H., Liu, M., Gershenwald, J. E., Xie, K., Sawaya, R., & Huang, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2674 · Cited by 393
“The role of activated Stat3 in oncogenesis is manifested presumably through its critical role in the expression of many genes key to the regulation of multiple aspects of tumor cell survival, growth, and angiogenesis and evasion of immune surveillance (19, 20 ), such as cyclin D1, c-myc, vascular endothelial growth fa…”
BackgroundHilfiker-Kleiner, D., Hilfiker, A., Fuchs, M., Kaminski, K., Schaefer, A., Schieffer, B., Hillmer, A., Schmiedl, A., Ding, Z., Podewski, E., et al. (2004) · Circulation Research · doi:10.1161/01.res.0000134921.50377.61 · Cited by 385
Dysregulated molecular networks in head and neck carcinogenesis
Molinolo, A. A., Amornphimoltham, P., Squarize, C. H., Castilho, R. M., Patel, V., & Gutkind, J. S. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2008.07.011 · Cited by 385
Iwamaru, A., Szymanski, S., Iwado, E., Aoki, H., Yokoyama, T., Fokt, I., Hess, K., Conrad, C., Madden, T., Sawaya, R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210031 · Cited by 370
Signaling Pathways in Cancer and Embryonic Stem Cells
Dreesen, O., & Brivanlou, A. H. (2007) · Stem Cell Reviews · doi:10.1007/s12015-007-0004-8 · Cited by 357
Chan, K. S., Sano, S., Kiguchi, K., Anders, J., Komazawa, N., Takeda, J., & DiGiovanni, J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421032 · Cited by 356
Ernst, M., Najdovska, M., Grail, D., Lundgren-May, T., Buchert, M., Tye, H., Matthews, V. B., Armes, J., Bhathal, P. S., Hughes, N. R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34944 · Cited by 350
STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3
Liu, L., McBride, K. M., & Reich, N. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501643102 · Cited by 348
Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer
Kusmartsev, S., & Gabrilovich, D. I. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0048-z · Cited by 346
Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients
Di Tomaso, T., Mazzoleni, S., Wang, E., Sovena, G., Clavenna, D., Franzin, A., Mortini, P., Ferrone, S., Doglioni, C., Marincola, F. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2730 · Cited by 344
Alternative Activation of STAT1 and STAT3 in Response to Interferon-γ
Qing, Y., & Stark, G. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406413200 · Cited by 316
Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
Godwin, P., Baird, A. M., Heavey, S., Barr, M. P., O’Byrne, K. J., & Gately, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00120 · Cited by 296
Formononetin: A Review of Its Anticancer Potentials and Mechanisms
Tay, K.-C., Tan, L. T.-H., Chan, C. K., Hong, S. L., Chan, K.-G., Yap, W. H., Pusparajah, P., Lee, L.-H., & Goh, B.-H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00820 · Cited by 294
Interleukin-6 and its receptor: from bench to bedside
Scheller, J., & Rose-John, S. (2006) · Medical Microbiology and Immunology · doi:10.1007/s00430-006-0019-9 · Cited by 292
Canonical and non-canonical JAK–STAT signaling
Li, W. X. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.008 · Cited by 290
A PANorama of PAX genes in cancer and development
Robson, E. J. D., He, S.-J., & Eccles, M. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1778 · Cited by 283
STAT1 as a key modulator of cell death
Kim, H. S., & Lee, M.-S. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2006.09.003 · Cited by 279
Subramaniam, A., Shanmugam, M. K., Perumal, E., Li, F., Nachiyappan, A., Dai, X., Swamy, S. N., Ahn, K. S., Kumar, A. P., Tan, B. K. H., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.10.002 · Cited by 278
Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin
Ng, D. C. H., Lin, B. H., Lim, C. P., Huang, G., Zhang, T., Poli, V., & Cao, X. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200503021 · Cited by 278
Wang, R., Cherukuri, P., & Luo, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413930200 · Cited by 275
The Biology of Epidermal Growth Factor Receptor in Lung Cancer
Scagliotti, G. V., Selvaggi, G., Novello, S., & Hirsch, F. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040007 · Cited by 270
Regulation of translocator protein 18kDa (TSPO) expression in health and disease states☆
Batarseh, A., & Papadopoulos, V. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.06.013 · Cited by 270
Guryanova, O. A., Wu, Q., Cheng, L., Lathia, J. D., Huang, Z., Yang, J., MacSwords, J., Eyler, C. E., McLendon, R. E., Heddleston, J. M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.004 · Cited by 260
Dechow, T. N., Pedranzini, L., Leitch, A., Leslie, K., Gerald, W. L., Linkov, I., & Bromberg, J. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404100101 · Cited by 254
Self-citationThe JAK/STAT Pathway in Model Organisms
Hou, S. X., Zheng, Z., Chen, X., & Perrimon, N. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00376-3 · Cited by 251
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Sebe-Pedros, A., de Mendoza, A., Lang, B. F., Degnan, B. M., & Ruiz-Trillo, I. (2011) · Molecular Biology and Evolution · doi:10.1093/molbev/msq309 · Cited by 195
Musolino, C., Allegra, A., Innao, V., Allegra, A. G., Pioggia, G., & Gangemi, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/1852517 · Cited by 168
The role of IL-11 in immunity and cancer
Xu, D. H., Zhu, Z., Wakefield, M. R., Xiao, H., Bai, Q., & Fang, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.004 · Cited by 134
Looyenga, B. D., Hutchings, D., Cherni, I., Kingsley, C., Weiss, G. J., & MacKeigan, J. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030820 · Cited by 120
Naphthoquinones: A continuing source for discovery of therapeutic antineoplastic agents
Qiu, H., Wang, P., Lin, H., Tang, C., Zhu, H., & Yang, Y. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13141 · Cited by 118
Schlessinger, K., & Levy, D. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0317 · Cited by 112
Campana, L., Starkey Lewis, P. J., Pellicoro, A., Aucott, R. L., Man, J., O’Duibhir, E., Mok, S. E., Ferreira-Gonzalez, S., Livingstone, E., Greenhalgh, S. N., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701247 · Cited by 107
Kim, D. J., Tremblay, M. L., & DiGiovanni, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010290 · Cited by 83
Courapied, S., Sellier, H., de Carné Trécesson, S., Vigneron, A., Bernard, A.-C., Gamelin, E., Barré, B., & Coqueret, O. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.092304 · Cited by 76
Mandal, T., Bhowmik, A., Chatterjee, A., Chatterjee, U., Chatterjee, S., & Ghosh, M. K. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.04.003 · Cited by 65
The expression of microRNA‐203 during human skin morphogenesis
Wei, T., Orfanidis, K., Xu, N., Janson, P., Ståhle, M., Pivarcsi, A., & Sonkoly, E. (2010) · Experimental Dermatology · doi:10.1111/j.1600-0625.2010.01118.x · Cited by 60
Gene expression alterations in activated human T-cells induced by modeled microgravity
Ward, N. E., Pellis, N. R., Risin, S. A., & Risin, D. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20988 · Cited by 47
Metadata
- Authors
- Bromberg, J.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-05-01
- Volume
- 109
- Issue
- 9
- Pages
- 1139-1142
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2079715612
- Cited by
- 770
- References
- 45
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.